Literature DB >> 26760812

Acute myeloid leukemia: update in diagnosis and treatment in Brazil.

Ricardo Helman1, Fabio Pires de Souza Santos1, Belinda Simões2, Elias Hallack Atta3, Fernando Callera4, Jane de Almeida Dobbin5, Éderson Roberto Mattos6, Angelo Atalla7, Angelo Maiolino8, Maria Aparecida Zanichelli9, Cristiane Fração Diefenbach10, Marcia Torresan Delamain11, Nelson Hamerschlak1.   

Abstract

OBJECTIVE: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009.
METHODS: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and perform bone marrow transplantation. Data were collected from clinical charts of patients with acute myeloid leukemia treated at the said centers between 2005 and 2009. The availability for immunophenotyping and cytogenetic tests was assessed.
RESULTS: During 2009, a total of 345 new cases of acute myeloid leukemia were diagnosed. Differences were noted in the tests performed between patients who initiated treatment at the center and those referred for treatment. Of the participating centers, 72% conducted some type of molecular study in acute myeloid leukemia upon diagnosis.
CONCLUSION: Treatment for acute myeloid leukemia in Brazil shows significantly inferior results when compared to other centers worldwide.

Entities:  

Year:  2011        PMID: 26760812     DOI: 10.1590/S1679-45082011AO1853

Source DB:  PubMed          Journal:  Einstein (Sao Paulo)        ISSN: 1679-4508


  1 in total

1.  Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.

Authors:  Tarcila Santos Datoguia; Elvira Deolinda Rodrigues Pereira Velloso; Ricardo Helman; Juliane Garcez Musacchio; Marco Aurélio Salvino; Rodolfo Almeida Soares; Marcia Higashi; Adriana Valente Fadel; Rodrigo Santucci Alves E Silva; Nelson Hamerschlak; Fabio Pires de Souza Santos; Paulo Vidal Campregher
Journal:  Med Oncol       Date:  2018-09-05       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.